Pfizer Inc and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine by December after final trial results indicated it had a 95 percent success rate and no serious side effect. The vaccine's efficacy was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people, the drug makers said on Wednesday.
The U.S. Food & Drug Administration could grant emergency-use by the middle of December, BioNTech Chief Executive Ugur Sahin told Reuters TV. Conditional approval in the European Union could be secured in the second half of December, he added. "If all goes well I could imagine that we gain approval in the second half of December and start deliveries before Christmas, but really only if all goes positively," he said.
The success rate of the vaccine developed by the U.S. drugmaker and German partner BioNTech was far higher than what regulators had said would have been acceptable. Experts said it was a significant achievement in the race to end the pandemic.
Of the 170 volunteers who contracted COVID-19 in Pfizer's trial involving over 43,000 people, 162 had received a placebo and not the vaccine, meaning the vaccine was 95% effective. Of the 10 people who had severe COVID-19, one had received the vaccine.
Covid Vaccine: Pfizer, BioNTech claim normal life will be back by the winters of 2021
Corona's 2 effective vaccines arrived in a week, Over 90% Effective